Adare Pharmaceuticals

Adare Pharmaceuticals

A pharmaceutical company focused on making products to improve the microbiome.

All edits by  Michael Mangus 

Edits on 14 Mar, 2019
Michael Mangus
Michael Mangus approved a suggestion from Golden's AI on 14 Mar, 2019
Edits made to:
Article (+11/-11 characters)

In March 2019, Adare Pharmaceuticals (Adare) announced positive results from its Phase IIb study (FLUTETM) for one of its rare disease investigational products, APT-1011 (AdvaTab® FluticasoneFluticasone) for Eosinophilic Esophagitis (EoE). Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease. The disease is characterized by eosinophilic infiltration of the esophagus which can put patients at risk for food imaction due to inflammation and development of strictures and narrowing of the esophagus. APT-1011 is a novel formulation incorporating Adare's proprietary AdvaTab® technology is a fluticasone product. Fluticasone is a corticosteroid treatment that reduces swelling or inflammation in the nasal passages. APT-1011 is an oral formulation of fluticasone that allows topical delivery to the esophagus and minimizes time in the oral cavity. At the time of this announcement there were no FDA approved EoE treatments available in the US.EoE treatments include food elimination diets, off-label use of proton pump inhibitors and glucocorticoid steroid formulations.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.